We are live on ! Find out more
HMC

Harvard Management Company Portfolio holdings

AUM $1.82B
1-Year Est. Return 26.23%
This Fund
S&P 500
This Quarter Est. Return
-4.77%
1 Year Est. Return
+26.23%
3 Year Est. Return
+156.3%
5 Year Est. Return
+133.98%
10 Year Est. Return
+221.37%
AUM
$804M
AUM Growth
-$60M
Cap. Flow
+$17.5M
Cap. Flow %
2.18%
Top 10 Hldgs %
81.16%
Holding
47
New
2
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
GRAB icon
Grab
GRAB
+$11.9M
2
KITT icon
Nauticus Robotics
KITT
+$4.43M
3
LAUR icon
Laureate Education
LAUR
+$1.15M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Communication Services 47.87%
2 Healthcare 20.16%
3 Consumer Discretionary 14.29%
4 Technology 12.36%
5 Industrials 3.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RKLB icon
26
Rocket Lab Corp
RKLB
$46.7B
$4.07M 0.51%
1,000,000
– –
FULC icon
27
Fulcrum Therapeutics
FULC
$288M
$3.32M 0.41%
410,714
– –
AFRM icon
28
Affirm
AFRM
$26.3B
$3.26M 0.41%
173,560
– –
CFLT
29
DELISTED
Confluent
CFLT
$3.1M 0.39%
130,383
– –
SANA icon
30
Sana Biotechnology
SANA
$977M
$2.81M 0.35%
468,749
– –
GBIO
31
DELISTED
Generation Bio
GBIO
$2.71M 0.34%
51,035
– –
VIGL
32
DELISTED
Vigil Neuroscience
VIGL
$2.63M 0.33%
289,460
– –
TNGX icon
33
Tango Therapeutics
TNGX
$4.69B
$2.56M 0.32%
708,385
– –
PCTTW
34
PureCycle Technologies Inc Warrant
PCTTW
$10.9M
$2.43M 0.3%
714,285
– –
TNYA icon
35
Tenaya Therapeutics
TNYA
$170M
$1.95M 0.24%
673,270
– –
KITT icon
36
Nauticus Robotics
KITT
$6.91M
$1.8M 0.22%
+193
New +$4.43M
PRAX icon
37
Praxis Precision Medicines
PRAX
$8.9B
$1.77M 0.22%
51,901
– –
SRZN icon
38
Surrozen
SRZN
$255M
$1.67M 0.21%
55,123
– –
DYN icon
39
Dyne Therapeutics
DYN
$4.89B
$1.36M 0.17%
107,252
– –
PACB icon
40
Pacific Biosciences
PACB
$404M
$1.33M 0.17%
229,144
– –
XLO icon
41
Xilio Therapeutics
XLO
$59.9M
$1.21M 0.15%
29,719
– –
DBTX
42
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$1.14M 0.14%
328,798
– –
LAUR icon
43
Laureate Education
LAUR
$5.24B
$1.07M 0.13%
+101,804
New +$1.15M
MCRB icon
44
Seres Therapeutics
MCRB
$48.4M
$846K 0.11%
6,592
– –
PRDS
45
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$740K 0.09%
400,000
– –
DNTH icon
46
Dianthus Therapeutics
DNTH
$6.15B
$469K 0.06%
20,788
– –
IRON icon
47
Disc Medicine
IRON
$3.03B
$410K 0.05%
8,333
– –
1
2

Similar funds

DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $1.82B AUM 19.69% 1-Year Est. Return
SI
Standard Investments New York $1.83B AUM 4.12% 1-Year Est. Return
GC
Gobi Capital San Francisco, California $1.8B AUM 7.28% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
KAM
Kensington Asset Management Austin, Texas $1.84B AUM 13.95% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return
BP
BBR Partners New York $1.79B AUM 16.83% 1-Year Est. Return

Harvard Management Company's Q3 2022 Portfolio in Review

As of Q3 2022, Harvard Management Company held 47 positions worth $804M, down 6.9% from $864M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Trading was light in Q3 2022: portfolio turnover was 4.3%. Harvard Management Company opened 2 new positions and made no exits, leaving the 47-position portfolio largely intact.

By sector, the portfolio is most concentrated in Communication Services at 48% of assets, down from 52% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Harvard Management Company's largest Q3 2022 buy was Nauticus Robotics: 193 shares worth $1.8M.
  • Harvard Management Company added most to Grab in Q3 2022, an estimated $11.9M increase.
  • Harvard Management Company's ten largest holdings make up 81% of its $804M portfolio in Q3 2022.
  • Harvard Management Company opened 2 new positions and closed 0 in Q3 2022.
  • Harvard Management Company's portfolio value fell 6.9% quarter-over-quarter to $804M.

Based on Harvard Management Company's 13F filing for Q3 2022, filed 10 Nov 2022.